Medical Cannabis for the Treatment of Peripheral Neuropathy due to Diabetes: A Systematic Review
This systematic review highlights cannabinoids diabetic neuropathy pain relief, showing significant benefits in three of four trials. THC-containing products demonstrated the strongest efficacy for diabetic nerve pain. These findings provide…
Understanding President Trump’s Executive Order on Medical Cannabis Rescheduling
The federal medical marijuana rescheduling update under President Trump’s executive order aims to remove barriers to research, prescribing, and insurance coverage. This change would enable standardized treatment guidelines and evidence-based dosing…
President Trump’s Administration Reclassifies State-Licensed Medical Marijuana as Lower-Risk Drug
The state-licensed medical marijuana reclassified as lower-risk drug marks a significant policy shift by the Trump administration. This change may reduce regulatory barriers and expand research opportunities. Clinicians should monitor its impact on…
‘The wild west:’ How an Alberta recreational retailer is addressing health-related cannabis inquiries
An Alberta recreational cannabis retailer is facing increasing health-related cannabis inquiries from consumers. This highlights the critical knowledge gap where retail staff provide medical guidance without training. Addressing this gap is essential for…
New Medical Cannabis Dispensary Improves Kentucky Patient Access
Kentucky medical cannabis access has expanded with the opening of a new dispensary in Paducah. This development improves patient access to regulated cannabis medicine in western Kentucky. Patients now benefit from safer, tested cannabis products without…
Our Opinion: Pennsylvania Must Embrace Recreational Cannabis Legalization
Pennsylvania recreational cannabis legalization could significantly broaden patient access beyond current medical restrictions. This shift would impact clinical counseling and regulatory frameworks. Understanding these changes is essential for healthcare…
. @crescolabs CEO: Rescheduling Ushers in a New Era of Medical Cannabis Patient Care –
Medical cannabis rescheduling regulatory impact is poised to transform research and patient care. This shift could enable more rigorous clinical trials and standardized treatment protocols. Patients and clinicians should stay informed about evolving…
Some Medical Marijuana to Be Reclassified: Nationwide Legal Impact?
The federal medical marijuana reclassification clinical implications could change how cannabis-based medicines are prescribed and researched. This shift may improve access to FDA-approved cannabis medications. However, it does not legalize recreational…
Trump DOJ Deregulates Marijuana to the Dismay of Health Experts – The Washington Stand
The Trump DOJ deregulates marijuana, affecting federal marijuana policy and clinical access to cannabis medicines. These changes influence patient care and research opportunities. Health experts express concern over the implications of this policy shift.
Trump Administration Updates Medical Marijuana Schedule III Reclassification
The medical marijuana schedule III reclassification update marks a significant federal policy shift. This change reduces research barriers and improves clinical access. It paves the way for expanded clinical trials and standardized prescribing.
